2023 World Conference on Lung Cancer (Posters)-EP10.01. Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy

EP10.01. Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy of docetaxel as a subsequent treatment for non-small cell lung cancer (NSCLC) patients who have progressed to platinum-based chemotherapy and anti P-1/PD-L1 immunotherapy. The study included 65 patients and analyzed their demographic characteristics, treatments received, and survival outcomes. The median age of the patients was 67.0 years, with 67.7% being male. The majority of patients had adenocarcinoma (63.1%), followed by squamous-cell carcinoma (24.6%) and other histologies (12.3%). <br /><br />The objective response rate for docetaxel treatment was 21.0%, with a disease control rate of 42.1%. Around 55.7% of patients experienced toxicity from the treatment. The median progression-free survival (PFS) was 2.0 months, and the overall survival (OS) was 6.0 months. Approximately 24.6% of patients were long survivors. <br /><br />The study found that docetaxel displayed poor survival results for patients who had progressed to platinum-based chemotherapy and anti PD1/PD-L1 inhibitors. The presence of hepatic metastases was associated with poor survival, as shown in the multivariate analysis. In the univariate analysis, squamous cell carcinoma and extra thoracic metastatic disease were also associated with poor survival. <br /><br />These findings suggest the need for developing new therapies for NSCLC patients who have progressed to platinum-based chemotherapy and immunotherapy. The study highlights the importance of considering hepatic metastases and specific histologies when determining treatment options for these patients.

Asset Subtitle

Virginia Calvo de Juan

Meta Tag

Speaker Virginia Calvo de Juan

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

docetaxel

non-small cell lung cancer

NSCLC

platinum-based chemotherapy

anti PD1/PD-L1 immunotherapy

treatments received

survival outcomes

adenocarcinoma

squamous-cell carcinoma

hepatic metastases